Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Pennsylvania

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health to Therapeutic Risk Awareness

For years, this resource has served as a reliable hub for frequently updated information on diet, food, and general health. Visitors have relied on curated ideas, links, and pricing to make informed lifestyle choices, with content refreshed regularly to support ongoing wellness. This foundation in accessible health knowledge has always aimed to empower individuals navigating their personal well-being. As the landscape of health awareness evolves, so too does the scope of relevant concerns. Beyond everyday nutrition and general wellness, certain therapeutic exposures have emerged as critical topics for public understanding. One such area involves the use of disease-modifying therapies, where patients and their families may face complex decisions about treatment risks. In particular, exposure to Tysabri has been associated with a rare but serious condition known as progressive multifocal leukoencephalopathy (PML). For those affected in Pennsylvania, understanding the legal dimensions—such as the statute of limitations for filing a claim—becomes an essential part of managing the aftermath. This transition from general health guidance to specific therapeutic exposure concerns reflects a natural broadening of the health information mission, addressing not only prevention but also recourse when adverse outcomes occur.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV), a pathogen that typically remains dormant in healthy individuals but can reactivate in immunocompromised patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable and often includes progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual loss, and speech difficulties. Diagnosis is confirmed through brain imaging, typically MRI showing characteristic white matter lesions, and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). Because PML can mimic multiple sclerosis relapses, early recognition is challenging but critical.

Mechanism of Tysabri-Associated PML and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs normal immune surveillance of the brain. In patients harboring latent JCV, the reduced immune trafficking allows the virus to reactivate and infect oligodendrocytes, leading to demyelination and neuronal damage. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered when initiating and continuing therapy.

Adverse Event Data and Monitoring Requirements

Adverse event data from the FDA Adverse Event Reporting System (FAERS) show that Tysabri is associated with a wide range of reported symptoms, many of which overlap with PML manifestations. The most frequently reported events include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), and balance disorder (5,621 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the importance of distinguishing PML from common multiple sclerosis symptoms. The boxed warning instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations: Statute of Limitations in Pennsylvania

The adequacy of warnings regarding Tysabri and PML is a central issue in legal considerations for affected patients. The prescribing information includes a boxed warning, a Medication Guide, and enrollment in the restricted TOUCH Prescribing Program, which requires patients to read and sign an enrollment form acknowledging the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether these warnings were sufficiently communicated to patients or whether healthcare providers adequately monitored for early signs of PML. For patients who developed PML, the timeline between exposure and documented harm is critical. PML can occur after a few months to several years of Tysabri treatment, and the risk increases with cumulative exposure. The boxed warning notes that "longer treatment duration, especially beyond 2 years" is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period can complicate the determination of when the injury occurred relative to the statute of limitations. In Pennsylvania, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the date of discovery may be the date of diagnosis via MRI and JCV PCR testing, or the date when symptoms first became apparent. Because PML symptoms can be subtle and initially attributed to multiple sclerosis, the discovery date may be later than the actual onset. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to assess whether the claim falls within the statutory window. The attorney will need to gather medical records documenting the diagnosis, the duration of Tysabri use, and any prior immunosuppressant exposure. Evidence of inadequate warnings or failure to monitor may also be relevant.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the discovery date is typically the date of diagnosis via MRI and JCV PCR testing, or when symptoms first became apparent. Because PML symptoms can mimic multiple sclerosis, the discovery date may be later than actual onset. It is crucial to consult an attorney promptly to preserve your rights.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered when initiating and continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.